Return-to-Play Post-Myocarditis Safety Calculator

Clinical calculation support · Verify results before clinical use

Clinical Readiness Assessment

Enter follow-up findings to identify issues requiring specialist review before return to strenuous exercise or competitive sport.

RTPReview
Enter a number from 0 or greater. Timing alone does not establish readiness.
Enter 0–100 and interpret with imaging quality, reference ranges, and clinical history.
Symptom-free at presentHave cardiopulmonary symptoms fully resolved?
Cardiac troponin normalizedUse the treating clinician’s interpretation of serial results.
Inflammatory markers normalizedConsider CRP and other evidence of active inflammation.
Active myocardial inflammation / edema resolvedAssess CMR findings where indicated; biomarkers alone may not fully characterize inflammation.
Residual late gadolinium enhancement (LGE) on CMRPersistent LGE is not an automatic exclusion, but requires individualized risk assessment.
Clinically relevant ventricular arrhythmia detectedConsider ambulatory ECG and exercise testing.
Appropriate rhythm assessment completedUsually includes ambulatory ECG monitoring and exercise testing when indicated.

How to interpret this assessment

This is a conservative decision-support checklist, not a validated risk score and not an automatic sports-clearance instrument. It identifies unresolved findings for review by the treating cardiology or sports-cardiology team.

Key clinical considerations

  • Athletes should not participate in strenuous or competitive sport while symptoms or active myocardial inflammation/edema persist.
  • Assessment before return should consider ventricular function, cardiac biomarkers, CMR when indicated, ambulatory rhythm monitoring, and exercise testing.
  • Traditional guidance commonly recommends 3–6 months away from strenuous exercise for clinical myocarditis, followed by reassessment. The 2025 AHA/ACC statement allows earlier return in selected athletes when specified criteria are satisfied.
  • Persistent LGE alone does not automatically prohibit participation when LV systolic function is normal and clinically relevant arrhythmias are absent; individualized assessment and longitudinal surveillance remain important.
  • This checklist does not capture every risk modifier, including baseline ventricular dysfunction, myocarditis severity or etiology, genetic substrate, LGE extent/pattern, and sport-specific demands.

Why there is no automatic “cleared” result

Guidelines require integrated clinical assessment. This checklist flags issues for review rather than replacing specialist judgement or certifying clearance.

References

Drazner MH, Bozkurt B, Cooper LT Jr, et al.2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis. Journal of the American College of Cardiology. 2024. doi:10.1016/j.jacc.2024.10.080
Kim JH, Baggish AL, Levine BD, et al.Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2025;151:e716–e761. doi:10.1161/CIR.0000000000001297
Clinical disclaimer: For educational and clinical decision-support use only. This tool is not a substitute for individualized assessment by a qualified clinician and must not be used as sole authorization to resume exercise or competitive sport. Follow local protocols and applicable guidance. Seek urgent assessment for chest pain, syncope, new dyspnea, sustained palpitations, or clinical deterioration.